Cargando…

Distinct subcellular localization of E-cadherin between epithelioid angiomyolipoma and triphasic angiomyolipoma: A preliminary case-control study

Epithelioid angiomyolipoma (EAML) is a rare variant of angiomyolipoma (AML). Previous studies have demonstrated that epithelial (E-)cadherin is expressed in two subtypes of AML, EAML and triphasic AML; however, the expression pattern of E-cadherin remains unclear. In the present study, a preliminary...

Descripción completa

Detalles Bibliográficos
Autores principales: Bi, Xin-Gang, Guo, Lei, Wang, Xiao-Liang, Wei, Qian, Du, Qiang, Jiang, Wen-Hao, Zheng, Guang-Yuan, Zhang, Hong-Tu, Ma, Jian-Hui, Zheng, Shan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: D.A. Spandidos 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5494718/
https://www.ncbi.nlm.nih.gov/pubmed/28693223
http://dx.doi.org/10.3892/ol.2017.6272
_version_ 1783247712779501568
author Bi, Xin-Gang
Guo, Lei
Wang, Xiao-Liang
Wei, Qian
Du, Qiang
Jiang, Wen-Hao
Zheng, Guang-Yuan
Zhang, Hong-Tu
Ma, Jian-Hui
Zheng, Shan
author_facet Bi, Xin-Gang
Guo, Lei
Wang, Xiao-Liang
Wei, Qian
Du, Qiang
Jiang, Wen-Hao
Zheng, Guang-Yuan
Zhang, Hong-Tu
Ma, Jian-Hui
Zheng, Shan
author_sort Bi, Xin-Gang
collection PubMed
description Epithelioid angiomyolipoma (EAML) is a rare variant of angiomyolipoma (AML). Previous studies have demonstrated that epithelial (E-)cadherin is expressed in two subtypes of AML, EAML and triphasic AML; however, the expression pattern of E-cadherin remains unclear. In the present study, a preliminary case-control study was conducted to determine the expression pattern of E-cadherin between EAML and triphasic AML, the control, focusing on the subcellular localization and expression category of E-cadherin. No significant difference was identified in the age, sex, history of tuberous sclerosis, smoking and alcohol consumption between the two groups (P>0.05). In EAML, 9 patients were categorized as exhibiting a low risk of malignant behavior and the other two were categorized as exhibiting an intermediate or high risk of malignant behavior. The proportion of cases expressing E-cadherin, human melanoma black-45 (HMB45), melanoma antigen recognized by T cells 1 (Mart1/Melan A), smooth muscle actin and progesterone receptor were 95.5 (21/22), 95.5 (21/22), 86.4 (19/22), 77.3 (17/22) and 86.4% (19/22), respectively. E-cadherin was identified to be localized, using staining techniques, in the cell membrane and/or cytoplasm. The subcellular localization of E-cadherin was significantly different between EAML and triphasic AML; the majority of EAML cases revealed membranous and cytoplasmic staining, whereas triphasic AML cases demonstrated cytoplasmic staining (P=0.0093). The expression of E-cadherin may be positively associated with HMB45 (P=0.0044) and Mart1/Melan A (P=0.0049). The results of the present study identified that the subcellular localization of E-cadherin may be different between EAML and the control group of triphasic AML. Additionally, E-cadherin and melanocytic markers may be co-expressed in distinct subtypes of AML. A follow-up study with a large sample size to validate the results of the present study, followed by a mechanistic study based on cell lines to determine any significance, are warranted.
format Online
Article
Text
id pubmed-5494718
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher D.A. Spandidos
record_format MEDLINE/PubMed
spelling pubmed-54947182017-07-07 Distinct subcellular localization of E-cadherin between epithelioid angiomyolipoma and triphasic angiomyolipoma: A preliminary case-control study Bi, Xin-Gang Guo, Lei Wang, Xiao-Liang Wei, Qian Du, Qiang Jiang, Wen-Hao Zheng, Guang-Yuan Zhang, Hong-Tu Ma, Jian-Hui Zheng, Shan Oncol Lett Articles Epithelioid angiomyolipoma (EAML) is a rare variant of angiomyolipoma (AML). Previous studies have demonstrated that epithelial (E-)cadherin is expressed in two subtypes of AML, EAML and triphasic AML; however, the expression pattern of E-cadherin remains unclear. In the present study, a preliminary case-control study was conducted to determine the expression pattern of E-cadherin between EAML and triphasic AML, the control, focusing on the subcellular localization and expression category of E-cadherin. No significant difference was identified in the age, sex, history of tuberous sclerosis, smoking and alcohol consumption between the two groups (P>0.05). In EAML, 9 patients were categorized as exhibiting a low risk of malignant behavior and the other two were categorized as exhibiting an intermediate or high risk of malignant behavior. The proportion of cases expressing E-cadherin, human melanoma black-45 (HMB45), melanoma antigen recognized by T cells 1 (Mart1/Melan A), smooth muscle actin and progesterone receptor were 95.5 (21/22), 95.5 (21/22), 86.4 (19/22), 77.3 (17/22) and 86.4% (19/22), respectively. E-cadherin was identified to be localized, using staining techniques, in the cell membrane and/or cytoplasm. The subcellular localization of E-cadherin was significantly different between EAML and triphasic AML; the majority of EAML cases revealed membranous and cytoplasmic staining, whereas triphasic AML cases demonstrated cytoplasmic staining (P=0.0093). The expression of E-cadherin may be positively associated with HMB45 (P=0.0044) and Mart1/Melan A (P=0.0049). The results of the present study identified that the subcellular localization of E-cadherin may be different between EAML and the control group of triphasic AML. Additionally, E-cadherin and melanocytic markers may be co-expressed in distinct subtypes of AML. A follow-up study with a large sample size to validate the results of the present study, followed by a mechanistic study based on cell lines to determine any significance, are warranted. D.A. Spandidos 2017-07 2017-05-29 /pmc/articles/PMC5494718/ /pubmed/28693223 http://dx.doi.org/10.3892/ol.2017.6272 Text en Copyright: © Bi et al. This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License (https://creativecommons.org/licenses/by-nc-nd/4.0/) , which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made.
spellingShingle Articles
Bi, Xin-Gang
Guo, Lei
Wang, Xiao-Liang
Wei, Qian
Du, Qiang
Jiang, Wen-Hao
Zheng, Guang-Yuan
Zhang, Hong-Tu
Ma, Jian-Hui
Zheng, Shan
Distinct subcellular localization of E-cadherin between epithelioid angiomyolipoma and triphasic angiomyolipoma: A preliminary case-control study
title Distinct subcellular localization of E-cadherin between epithelioid angiomyolipoma and triphasic angiomyolipoma: A preliminary case-control study
title_full Distinct subcellular localization of E-cadherin between epithelioid angiomyolipoma and triphasic angiomyolipoma: A preliminary case-control study
title_fullStr Distinct subcellular localization of E-cadherin between epithelioid angiomyolipoma and triphasic angiomyolipoma: A preliminary case-control study
title_full_unstemmed Distinct subcellular localization of E-cadherin between epithelioid angiomyolipoma and triphasic angiomyolipoma: A preliminary case-control study
title_short Distinct subcellular localization of E-cadherin between epithelioid angiomyolipoma and triphasic angiomyolipoma: A preliminary case-control study
title_sort distinct subcellular localization of e-cadherin between epithelioid angiomyolipoma and triphasic angiomyolipoma: a preliminary case-control study
topic Articles
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5494718/
https://www.ncbi.nlm.nih.gov/pubmed/28693223
http://dx.doi.org/10.3892/ol.2017.6272
work_keys_str_mv AT bixingang distinctsubcellularlocalizationofecadherinbetweenepithelioidangiomyolipomaandtriphasicangiomyolipomaapreliminarycasecontrolstudy
AT guolei distinctsubcellularlocalizationofecadherinbetweenepithelioidangiomyolipomaandtriphasicangiomyolipomaapreliminarycasecontrolstudy
AT wangxiaoliang distinctsubcellularlocalizationofecadherinbetweenepithelioidangiomyolipomaandtriphasicangiomyolipomaapreliminarycasecontrolstudy
AT weiqian distinctsubcellularlocalizationofecadherinbetweenepithelioidangiomyolipomaandtriphasicangiomyolipomaapreliminarycasecontrolstudy
AT duqiang distinctsubcellularlocalizationofecadherinbetweenepithelioidangiomyolipomaandtriphasicangiomyolipomaapreliminarycasecontrolstudy
AT jiangwenhao distinctsubcellularlocalizationofecadherinbetweenepithelioidangiomyolipomaandtriphasicangiomyolipomaapreliminarycasecontrolstudy
AT zhengguangyuan distinctsubcellularlocalizationofecadherinbetweenepithelioidangiomyolipomaandtriphasicangiomyolipomaapreliminarycasecontrolstudy
AT zhanghongtu distinctsubcellularlocalizationofecadherinbetweenepithelioidangiomyolipomaandtriphasicangiomyolipomaapreliminarycasecontrolstudy
AT majianhui distinctsubcellularlocalizationofecadherinbetweenepithelioidangiomyolipomaandtriphasicangiomyolipomaapreliminarycasecontrolstudy
AT zhengshan distinctsubcellularlocalizationofecadherinbetweenepithelioidangiomyolipomaandtriphasicangiomyolipomaapreliminarycasecontrolstudy